AstraZeneca: Phase 3 Trial of Datopotamab Deruxtecan-Pembrolizumab Combo in Lung Cancer

 Daiichi Sankyo (TSE: 4568) today announced that the first patient has been dosed in the global, randomized TROPION-Lung07 phase 3 trial evaluating datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy, in patients with previously untreated advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with PD-L1 expression less than 50% (TPS<50%) and without actionable genomic alterations.

Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN).

Among patients with NSCLC, nearly half are diagnosed at an advanced stage and generally have a poor prognosis.1,2,3 While first-line treatment with pembrolizumab or other checkpoint inhibitors, with or without chemotherapy, has improved outcomes in patients with NSCLC without actionable genomic alterations, disease progression still occurs in the majority of patients.4,5

https://www.businesswire.com/news/home/20230127005397/en/TROPION-Lung07-Phase-3-Trial-Initiated-to-Evaluate-Datopotamab-Deruxtecan-in-Combination-with-Pembrolizumab-in-Patients-with-Previously-Untreated-Metastatic-Non-Small-Cell-Lung-Cancer